Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1
You may also be interested in...
Nanotek Biologics Deal Gives Green Cross Route To Russia
Following its entry into North America and China, Green Cross is set to make inroads into the rapidly growing Russian pharmaceutical market through a strategic partnership with Nanolek to commercialize the South Korean biopharmaceutical company’s biologics.
Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex
Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex